InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,277.51
(
0.80%
)
US TECH 100
18,064.80
(
0.02%
)
Dow Jones
38,686.32
(
1.51%
)
Brent Oil
81.30
(
0.00%
)
Bitcoin
67,584.75
(
0.15%
)
Post# of 252007
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 830
Posts 119741
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Whalatane post# 208760

Monday, 02/06/2017 12:25:00 PM

Monday, February 06, 2017 12:25:00 PM

Post# of 252007
Re: Repatha CVOT

To re-iterate (just to be clear), the trial was powered at 90% to detect a 15% relative reduction in the primary (risk of MACE) endpoint. So the actual result might not be as good as the 22% figure you cited based on modeling. For the primary-prevention patient group who participated in the trial, I’ll be genuinely impressed if the relative risk reduction is about 30%.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up